AR115021A1 - Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso - Google Patents
Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de usoInfo
- Publication number
- AR115021A1 AR115021A1 ARP190100774A ARP190100774A AR115021A1 AR 115021 A1 AR115021 A1 AR 115021A1 AR P190100774 A ARP190100774 A AR P190100774A AR P190100774 A ARP190100774 A AR P190100774A AR 115021 A1 AR115021 A1 AR 115021A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- methods
- differentiation factor
- agonist compounds
- growth differentiation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000556 agonist Substances 0.000 title abstract 2
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan en la presente compuestos que inducen pérdida de peso y que tratan la diabetes, dislipidemia, NASH y/u obesidad. También se proporcionan composiciones farmacéuticas que contienen dichos compuestos y usos terapéuticos de tales compuestos y composiciones, en donde dichos compuestos actúan como agonistas de GDF15 con un tiempo de acción prolongado y otras propiedades ventajosas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653759P | 2018-04-06 | 2018-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115021A1 true AR115021A1 (es) | 2020-11-18 |
Family
ID=66630339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100774A AR115021A1 (es) | 2018-04-06 | 2019-03-27 | Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11104711B2 (es) |
| EP (1) | EP3774860B1 (es) |
| JP (1) | JP7064618B2 (es) |
| KR (1) | KR102501922B1 (es) |
| CN (1) | CN112004821B (es) |
| AR (1) | AR115021A1 (es) |
| AU (1) | AU2019248535B2 (es) |
| BR (1) | BR112020017256A2 (es) |
| CA (1) | CA3096375C (es) |
| CL (1) | CL2020002564A1 (es) |
| CO (1) | CO2020012403A2 (es) |
| CR (1) | CR20200454A (es) |
| DO (1) | DOP2020000157A (es) |
| EA (1) | EA202092084A1 (es) |
| EC (1) | ECSP20062930A (es) |
| ES (1) | ES2937049T3 (es) |
| IL (1) | IL276980A (es) |
| JO (1) | JOP20200252B1 (es) |
| MA (1) | MA52228A (es) |
| MX (1) | MX2020010370A (es) |
| PE (1) | PE20212133A1 (es) |
| PH (1) | PH12020551656A1 (es) |
| SG (1) | SG11202009853VA (es) |
| TW (1) | TWI724392B (es) |
| UA (1) | UA127545C2 (es) |
| WO (1) | WO2019195091A1 (es) |
| ZA (1) | ZA202005385B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2832581C (en) | 2011-04-08 | 2022-08-23 | Yumei Xiong | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| AU2014296107B2 (en) | 2013-07-31 | 2018-07-26 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| PE20201350A1 (es) | 2018-04-09 | 2020-11-30 | Amgen Inc | Proteinas de fusion del factor de diferenciacion de crecimiento 15 |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| MX2022004311A (es) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. |
| AU2022333099A1 (en) | 2021-08-24 | 2024-02-08 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| EA024755B1 (ru) * | 2010-05-21 | 2016-10-31 | ИксЭль-ПРОТЕИН ГМБХ | Биосинтетические нерегулярные спиральные полипептиды пролина/аланина и их применения |
| DK2670847T3 (en) * | 2011-02-03 | 2017-01-16 | Xoma Technology Ltd | Methods and Materials for Improving Functional Protein Expression in Bacteria |
| BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| CA2896076C (en) * | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| RU2704285C2 (ru) | 2013-01-30 | 2019-10-25 | Нгм Байофармасьютикалз, Инк. | Композиции и способы применения для лечения метаболических расстройств |
| AU2014296215A1 (en) | 2013-07-31 | 2016-02-11 | Amgen Inc. | Stabilization of Fc-containing polypeptides |
| AU2014296107B2 (en) * | 2013-07-31 | 2018-07-26 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| WO2015200080A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Site specific protein modifications |
| JP6696915B2 (ja) | 2014-06-24 | 2020-05-20 | ノヴォ ノルディスク アー／エス | Ｍｉｃ−１融合タンパク質及びその使用 |
| CR20170027A (es) | 2014-07-30 | 2017-05-09 | Ngm Biopharmaceuticals Inc | Composiciones y métodos de uso para tratar trastornos metabólicos |
| WO2016069925A1 (en) | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| TWI703161B (zh) * | 2014-10-31 | 2020-09-01 | 美商Ｎｇｍ生物製藥公司 | 用於治療代謝病症之組合物及方法 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| TW201708249A (zh) | 2015-04-02 | 2017-03-01 | 健生生物科技公司 | 原毒素－ｉｉ變體及使用方法 |
| JP6946304B2 (ja) * | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| US11105818B2 (en) | 2016-01-15 | 2021-08-31 | Novo Nordisk A/S | MIC-1 receptor and uses thereof |
| JP2019510739A (ja) | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Ｇｆｒａｌ受容体療法 |
| WO2017147743A1 (zh) | 2016-02-29 | 2017-09-08 | 华为技术有限公司 | 视频优化方法、用户设备和网络设备 |
| EP3423097A4 (en) | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
-
2019
- 2019-03-26 TW TW108110400A patent/TWI724392B/zh active
- 2019-03-27 AR ARP190100774A patent/AR115021A1/es unknown
- 2019-03-29 ES ES19725879T patent/ES2937049T3/es active Active
- 2019-03-29 JP JP2020554477A patent/JP7064618B2/ja active Active
- 2019-03-29 MA MA052228A patent/MA52228A/fr unknown
- 2019-03-29 BR BR112020017256-1A patent/BR112020017256A2/pt unknown
- 2019-03-29 JO JOP/2020/0252A patent/JOP20200252B1/ar active
- 2019-03-29 WO PCT/US2019/024756 patent/WO2019195091A1/en active Application Filing
- 2019-03-29 EP EP19725879.1A patent/EP3774860B1/en active Active
- 2019-03-29 CA CA3096375A patent/CA3096375C/en active Active
- 2019-03-29 US US16/369,096 patent/US11104711B2/en active Active
- 2019-03-29 AU AU2019248535A patent/AU2019248535B2/en active Active
- 2019-03-29 PE PE2020001334A patent/PE20212133A1/es unknown
- 2019-03-29 EA EA202092084A patent/EA202092084A1/ru unknown
- 2019-03-29 CR CR20200454A patent/CR20200454A/es unknown
- 2019-03-29 UA UAA202005772A patent/UA127545C2/uk unknown
- 2019-03-29 SG SG11202009853VA patent/SG11202009853VA/en unknown
- 2019-03-29 KR KR1020207027912A patent/KR102501922B1/ko active IP Right Grant
- 2019-03-29 MX MX2020010370A patent/MX2020010370A/es unknown
- 2019-03-29 CN CN201980024748.6A patent/CN112004821B/zh active Active
-
2020
- 2020-08-17 DO DO2020000157A patent/DOP2020000157A/es unknown
- 2020-08-27 IL IL276980A patent/IL276980A/en unknown
- 2020-08-28 ZA ZA2020/05385A patent/ZA202005385B/en unknown
- 2020-10-01 CO CONC2020/0012403A patent/CO2020012403A2/es unknown
- 2020-10-02 CL CL2020002564A patent/CL2020002564A1/es unknown
- 2020-10-05 EC ECSENADI202062930A patent/ECSP20062930A/es unknown
- 2020-10-06 PH PH12020551656A patent/PH12020551656A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20062930A (es) | Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso | |
| CO2018004315A2 (es) | Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2 | |
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| SV2017005426A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| CL2016002382A1 (es) | Derivados de quinoxalina útiles como moduladores de fgfr quinasa | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
| CR20170108A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
| CO2021006482A2 (es) | Ureas cíclicas | |
| UY37221A (es) | Derivados de feniltriazol sustituidos con amida y usos de estos | |
| BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
| CL2017001301A1 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| CO2017011958A2 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| ECSP16078779A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| CL2015003286A1 (es) | (ciano-dimetil-metil)-(isoxazoles y -[1, 3, 4] tiadiazoles novedosos | |
| SV2018005731A (es) | Piperidinas sustituidas con halo como moduladores del receptor de orexina | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos |